

# Artemin/GFRα3 signaling axis is involved in the functional plasticity of sensory neurons in osteoarthritis pain



Ankita Gupta<sup>1,2,3</sup>, Uma Nair<sup>2</sup>, Connor Thonen-Fleck<sup>2</sup>, Santosh K. Mishra<sup>1,4,5</sup>, and B. Duncan X. Lascelles<sup>1,2,4,5</sup>

<sup>1</sup>Comparative Biomedical Sciences Graduate Program, <sup>2</sup>Translational Research in Pain, <sup>3</sup>Department of Clinical Sciences, <sup>4</sup>Department of Molecular Biomedical Sciences, <sup>5</sup>Comparative Pain Research and Education Center, NCSU, CVM.

## Background: Osteoarthritis (OA) Pain


■ The disease of OA is a significant contributor to the burden of chronic pain and disability in our society.




 Clinically efficacious and safe therapeutic options for OA pain management are limited.


## Background: Artemin in OA Pain

Artemin, an endogenous ligand is upregulated in OA pain and linked to limb use.



Increased circulating artemin in naturally occurring OA pain (A) dogs, (B) cats, (C) humans. n=4-38. Mean ± SEM. Student's t-test with two-tailed analysis. \*p≤0.05, \*\*p≤0.01.






Link between synovial/serum artemin and limb use. (A) Decrease in limb use (B) Grouped joint pain scores are associated with increased artemin (ng/ml) in dogs with OA pain (n=8-43).

# Goal and Hypothesis

Goal: Develop new clinically effective therapeutics for OA pain.

Hypothesis: Artemin sequestration systemically reverses
MIA-induced OA pain and hypersensitivity.




### Results

Blocking artemin signaling reverses OA pain at early and late time points




## Anti-artemin antibody rescues MIA-induced limb asymmetry on days 7 and 28



MIA induction causes limb asymmetry and an anti-artemin antibody alleviates limb disuse. Hindlimb Symmetry Index at baseline, days 7 (A), 14, 28 (B) and then 2, 5, and 24 hrs after anti-artemin or anti-IgG antibody administration (i.p.). \*compares MIA/IgG and MIA/anti-artemin. Mean  $\pm$  SD. N  $\geq$ 6 each group and time point (\* = p<0.05; \*\*\*\* = p<0.001). 2-way ANOVA with repeated measures and Holm-Sidak multiple comparisons test.

#### Anti-artemin antibody rescues MIA-induced hypersensitivity on day 7




Baseline Day 7

2 hrs


5 hrs 24 hrs

An anti-artemin antibody alleviates hyperalgesia in the MIA model of OA pain. Anti-artemin mAb (i.p.) alleviates MIA-associated hypersensitivity to mechanical (A), hot (B), and cold (C) in early inflammatory OA pain (day 7 post MIA). Anti-artemin was effective up to 24 hrs post mAb. Mean ± SD, n≥6 each group and time point. 2-way ANOVA with repeated measures and Geisser—Greenhouse and Sidak corrections, \*compares MIA/IgG and MIA/anti-artemin. \*\*\*\*p≤0.0001.

## Methods: Timeline



Histologic confirmation of OA




#### Conclusions

- MIA OA pain model exhibits limb disuse and hypersensitivity.
- Anti-artemin antibody reverses early inflammatory and late chronic pain.

#### Future Directions

- Elucidate the role of artemin/GFRα3 signaling in OA pain.
- Identify putative targets for developing safe and effective treatments.



# Acknowledgements and References

No conflicts of interest to declare.

Research and Student Support: Donations to the Translational Research in Pain Program, Salary release for Dr. Duncan Lascelles References:

- Gupta, A. et al. Serum artemin is not correlated with sensitivity within dogs with naturally occurring osteoarthritis pain. Sci Rep 11, 6682, doi:10.1038/s41598-021-85976-y (2021).
- Minnema, L., Gupta, A., Mishra, S. K. & Lascelles, B. D. X. Investigating the Role of Artemin and Its Cognate Receptor, GFRalpha3, in Osteoarthritis Pain. *Front Neurosci* **16**, 738976, doi:10.3389/fnins.2022.738976 (2022).
- Minnema, L. *et al.* Correlation of Artemin and GFRalpha3 With Osteoarthritis Pain: Early Evidence From Naturally Occurring Osteoarthritis-Associated Chronic Pain in Dogs. *Front Neurosci* **14**, 77, doi:10.3389/fnins.2020.00077 (2020).
- Alexander, G. C., Stoller, K. B., Haffajee, R. L. & Saloner, B. An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. *Ann Intern Med* 173, 57-58, doi:10.7326/M20-1141 (2020).

Contact Info: Ankita Gupta, agupta33@ncsu.edu